NO135828B - - Google Patents

Download PDF

Info

Publication number: NO135828B
Authority: NO; Norway
Prior art keywords: estradiol; skin; day; effect; action
Prior art date: 1971-04-21

Application number

NO1275/72A

Other languages

English (en)

Norwegian (no)

Other versions

NO135828C (da

Inventor

P C Wirth

Original Assignee

Sogeras

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1971-04-21

Filing date

1972-04-13

Publication date

1977-02-28

1972-04-13 Application filed by Sogeras filed Critical Sogeras

1977-02-28 Publication of NO135828B publication Critical patent/NO135828B/no

1977-06-08 Publication of NO135828C publication Critical patent/NO135828C/no

Links

229960005309 estradiol Drugs 0.000 claims description 26
229930182833 estradiol Natural products 0.000 claims description 15
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 14
230000009471 action Effects 0.000 claims description 8
238000000034 method Methods 0.000 claims description 8
210000004400 mucous membrane Anatomy 0.000 claims description 8
230000000699 topical effect Effects 0.000 claims description 8
150000004703 alkoxides Chemical class 0.000 claims description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
125000000217 alkyl group Chemical group 0.000 claims description 4
-1 alkyl sulphate Chemical compound 0.000 claims description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
230000003054 hormonal effect Effects 0.000 claims description 3
231100000508 hormonal effect Toxicity 0.000 claims description 3
150000001347 alkyl bromides Chemical class 0.000 claims description 2
125000004432 carbon atom Chemical group C* 0.000 claims description 2
210000004209 hair Anatomy 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
230000008569 process Effects 0.000 claims description 2
229910021653 sulphate ion Inorganic materials 0.000 claims 1
230000000694 effects Effects 0.000 description 26
150000001875 compounds Chemical class 0.000 description 24
210000003491 skin Anatomy 0.000 description 20
241001465754 Metazoa Species 0.000 description 17
230000007423 decrease Effects 0.000 description 16
238000011282 treatment Methods 0.000 description 16
239000000243 solution Substances 0.000 description 13
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 12
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
241000700159 Rattus Species 0.000 description 9
238000012360 testing method Methods 0.000 description 8
239000006071 cream Substances 0.000 description 7
230000001076 estrogenic effect Effects 0.000 description 6
229960003604 testosterone Drugs 0.000 description 6
230000002354 daily effect Effects 0.000 description 5
229940011871 estrogen Drugs 0.000 description 5
239000000262 estrogen Substances 0.000 description 5
230000012173 estrus Effects 0.000 description 5
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 4
206010039792 Seborrhoea Diseases 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
210000000981 epithelium Anatomy 0.000 description 4
229960002568 ethinylestradiol Drugs 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000000047 product Substances 0.000 description 4
208000008742 seborrheic dermatitis Diseases 0.000 description 4
210000002374 sebum Anatomy 0.000 description 4
239000000126 substance Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
230000001476 alcoholic effect Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000011734 sodium Substances 0.000 description 3
150000003431 steroids Chemical class 0.000 description 3
238000003756 stirring Methods 0.000 description 3
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 2
208000002874 Acne Vulgaris Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
KIWBPDUYBMNFTB-UHFFFAOYSA-N Ethyl hydrogen sulfate Chemical compound CCOS(O)(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-N 0.000 description 2
206010046914 Vaginal infection Diseases 0.000 description 2
201000008100 Vaginitis Diseases 0.000 description 2
206010000496 acne Diseases 0.000 description 2
239000003098 androgen Substances 0.000 description 2
102000001307 androgen receptors Human genes 0.000 description 2
108010080146 androgen receptors Proteins 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
210000003756 cervix mucus Anatomy 0.000 description 2
230000008859 change Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000006266 etherification reaction Methods 0.000 description 2
QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 description 2
230000035876 healing Effects 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
239000000203 mixture Substances 0.000 description 2
239000008188 pellet Substances 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
210000001732 sebaceous gland Anatomy 0.000 description 2
230000028327 secretion Effects 0.000 description 2
230000001568 sexual effect Effects 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
210000001550 testis Anatomy 0.000 description 2
210000001215 vagina Anatomy 0.000 description 2
HLCRYAZDZCJZFG-BDXSIMOUSA-N (8s,9s,13s,14s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene Chemical compound C1CC2=CC=CC=C2[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 HLCRYAZDZCJZFG-BDXSIMOUSA-N 0.000 description 1
YZWKKMVJZFACSU-UHFFFAOYSA-N 1-bromopentane Chemical class CCCCCBr YZWKKMVJZFACSU-UHFFFAOYSA-N 0.000 description 1
WPWHSFAFEBZWBB-UHFFFAOYSA-N 1-butyl radical Chemical compound [CH2]CCC WPWHSFAFEBZWBB-UHFFFAOYSA-N 0.000 description 1
206010027654 Allergic conditions Diseases 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
206010006326 Breath odour Diseases 0.000 description 1
HNKHISDZGZYDDU-WFEUEMSSSA-N COC1CC2CC=C3C4=CC=C[C@@]4(C)CC[C@@H]3[C@H]2CC1 Chemical compound COC1CC2CC=C3C4=CC=C[C@@]4(C)CC[C@@H]3[C@H]2CC1 HNKHISDZGZYDDU-WFEUEMSSSA-N 0.000 description 1
241000700198 Cavia Species 0.000 description 1
208000003322 Coinfection Diseases 0.000 description 1
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010067572 Oestrogenic effect Diseases 0.000 description 1
206010068319 Oropharyngeal pain Diseases 0.000 description 1
201000007100 Pharyngitis Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
206010047786 Vulvovaginal discomfort Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000032683 aging Effects 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000002280 anti-androgenic effect Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
239000000051 antiandrogen Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
229940125687 antiparasitic agent Drugs 0.000 description 1
239000003899 bactericide agent Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229960001338 colchicine Drugs 0.000 description 1
229940124558 contraceptive agent Drugs 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000008602 contraction Effects 0.000 description 1
239000012043 crude product Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
201000010251 cutis laxa Diseases 0.000 description 1
229960001760 dimethyl sulfoxide Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000001135 feminizing effect Effects 0.000 description 1
210000000497 foam cell Anatomy 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
201000000079 gynecomastia Diseases 0.000 description 1
208000024963 hair loss Diseases 0.000 description 1
230000003676 hair loss Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000000155 melt Substances 0.000 description 1
230000009245 menopause Effects 0.000 description 1
230000005906 menstruation Effects 0.000 description 1
WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
229940127234 oral contraceptive Drugs 0.000 description 1
239000003539 oral contraceptive agent Substances 0.000 description 1
230000027758 ovulation cycle Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
230000002488 pyknotic effect Effects 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
210000001625 seminal vesicle Anatomy 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000002884 skin cream Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
208000003265 stomatitis Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000002381 testicular Effects 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
AAAQKTZKLRYKHR-UHFFFAOYSA-N triphenylmethane Chemical compound C1=CC=CC=C1C(C=1C=CC=CC=1)C1=CC=CC=C1 AAAQKTZKLRYKHR-UHFFFAOYSA-N 0.000 description 1
201000010653 vesiculitis Diseases 0.000 description 1
208000002003 vulvitis Diseases 0.000 description 1
239000013585 weight reducing agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/008—Preparations for oily hair
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Birds (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)

NO1275/72A 1971-04-21 1972-04-13 NO135828C (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB1049671		1971-04-21

Publications (2)

Publication Number	Publication Date
NO135828B true NO135828B (da)	1977-02-28
NO135828C NO135828C (da)	1977-06-08

Family

ID=9968924

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO1275/72A NO135828C (da)	1971-04-21	1972-04-13

Country Status (18)

Country	Link
JP (1)	JPS511711B1 (da)
AR (1)	AR193726A1 (da)
AT (1)	AT320873B (da)
AU (1)	AU449978B2 (da)
BE (1)	BE780488A (da)
BR (1)	BR7202453D0 (da)
CA (1)	CA969928A (da)
CH (1)	CH537911A (da)
DE (1)	DE2215499C2 (da)
DK (1)	DK128736B (da)
FR (1)	FR2133579B1 (da)
GB (1)	GB1337198A (da)
IE (1)	IE36277B1 (da)
IL (1)	IL39090A (da)
LU (1)	LU64959A1 (da)
NL (1)	NL154514B (da)
NO (1)	NO135828C (da)
PH (1)	PH14937A (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2350315C2 (de) *	1973-10-06	1984-01-12	Johnson & Johnson GmbH, 4000 Düsseldorf	Pharmazeutische und kosmetische Präparate zur äußerlichen Anwendung
NL7800762A (nl) *	1978-01-20	1979-07-24	Acf Chemiefarma Nv	Vloeibare, voor injectie geschikte farmaceu- tische samenstellingen.
CN110003298B (zh) *	2019-03-22	2021-04-27	中国人民解放军军事科学院防化研究院	一种普罗雌烯的合成方法
CN113480588A (zh) *	2021-06-16	2021-10-08	南雄阳普医疗科技有限公司	一种甲丙雌二醚的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE17572C (de) *			C. poppenhusen in Hamburg	Verfahren und Apparate zur Herstellung von Bürsten
DE3C (de) *	1877-07-03		H. ZWINGENBERGER zu Ernstthal bei Chemnitz	Einrichtung von Rundwirkmaschinen zur Herstellung von Prefsmustern

1971
- 1971-04-21 GB GB1049671*[A patent/GB1337198A/en not_active Expired
1972
- 1972-03-10 BE BE780488A patent/BE780488A/xx not_active IP Right Cessation
- 1972-03-14 LU LU64959D patent/LU64959A1/xx unknown
- 1972-03-15 FR FR7208927A patent/FR2133579B1/fr not_active Expired
- 1972-03-16 CH CH406572A patent/CH537911A/fr not_active IP Right Cessation
- 1972-03-27 IL IL39090A patent/IL39090A/en unknown
- 1972-03-29 DE DE2215499A patent/DE2215499C2/de not_active Expired
- 1972-04-05 JP JP47034301A patent/JPS511711B1/ja active Pending
- 1972-04-06 CA CA139,098A patent/CA969928A/en not_active Expired
- 1972-04-11 IE IE472/72A patent/IE36277B1/xx unknown
- 1972-04-11 NL NL727204812A patent/NL154514B/xx not_active IP Right Cessation
- 1972-04-12 AU AU41045/72A patent/AU449978B2/en not_active Expired
- 1972-04-12 DK DK176972AA patent/DK128736B/da not_active IP Right Cessation
- 1972-04-13 NO NO1275/72A patent/NO135828C/no unknown
- 1972-04-19 PH PH13465A patent/PH14937A/en unknown
- 1972-04-20 BR BR2453/72A patent/BR7202453D0/pt unknown
- 1972-04-21 AR AR241612A patent/AR193726A1/es active
- 1972-04-21 AT AT355172A patent/AT320873B/de active

Also Published As

Publication number	Publication date
BE780488A (fr)	1972-07-03
FR2133579B1 (da)	1975-02-07
IE36277L (en)	1972-10-21
JPS511711B1 (da)	1976-01-20
IL39090A (en)	1976-12-31
AU4104572A (en)	1973-10-18
NL154514B (nl)	1977-09-15
AU449978B2 (en)	1974-06-10
CA969928A (en)	1975-06-24
CH537911A (fr)	1973-06-15
DE2215499C2 (de)	1974-03-21
DE2215499B1 (de)	1973-08-23
IE36277B1 (en)	1976-09-29
AR193726A1 (es)	1973-05-22
IL39090A0 (en)	1972-05-30
DK128736B (da)	1974-06-24
GB1337198A (en)	1973-11-14
AT320873B (de)	1975-03-10
FR2133579A1 (da)	1972-12-01
NO135828C (da)	1977-06-08
PH14937A (en)	1982-01-29
LU64959A1 (da)	1972-07-10
NL7204821A (da)	1972-10-24
BR7202453D0 (pt)	1973-07-17

Publication	Publication Date	Title
Di Renzo et al.	2020	Progesterone: History, facts, and artifacts
BG99178A (bg)	1995-05-31	Контрацептивен метод,използващ конкурентни прогестеронови антагонисти,и нови съединения,подходящи за приложението му
JP4368945B2 (ja)	2009-11-18	新規１９―ノループレグネン誘導体類
KR100243537B1 (ko)	2000-02-01	에스트라-1,3,5(10)-트리엔 유도체를 함유한 약제학적 조성물
KR20090094437A (ko)	2009-09-07	상승-약량 연장 주기 요법을 이용한 호르몬 치료 방법
Parkes et al.	1938	Interruption of Early Pregnancy by Orally Active Oestrogens
Ferin	1956	A new substance with progestational activity
US20240390314A1 (en)	2024-11-28	The use of the active compound in the prevention or treatment of ovarian dysfunction diseases
Hartman et al.	1930	The anterior lobe and menstruation
JP2004155779A (ja)	2004-06-03	更年期症の予防・治療用経口組成物
Madjerek et al.	1960	Allylestrenol, a pregnancy maintaining oral gestagen
ES2273061T3 (es)	2007-05-01	Agentes moduladores de receptores de progesterona con actividad antigonadotropa elevada para el control de fertilidad femenina y para la terapia por reemplazo hormonal.
NO135828B (da)	1977-02-28
Nathanson et al.	1938	Nature of the action of testosterone on genital tract of the immature female rat.
US4053489A (en)	1977-10-11	Oestratriene diethers
RU2364411C1 (ru)	2009-08-20	Средство и способ профилактики рецидива кист яичников
GREENBLATT et al.	1950	Physiologic effectiveness of oral progesterone
Robertson et al.	1930	OVAEIAN HORMONE EFFECTS IN OVARIECTOMIZED MONKEYS
Kubli-Garfias	1987	Modulatory action of 5-reduced androgens and progestins on the excitability of CNS and smooth muscle
UA113283C2 (xx)	2017-01-10	19-норстероїди і їх застосування для лікування прогестеронзалежних станів
Doisy	1941	The estrogenic substances
Korenchevsky	1937	Bisexual Properties and Co-operative Activity of Sex Hormones
TW200911824A (en)	2009-03-16	8-beta-substituted estratrienes as selectively active estrogens
Melinkoff	1950	Questionable necessity of the corpus luteum
Allen	1941	The chemical and physiological properties, and clinical uses of the corpus luteum hormone, progesterone